Oncology Innovation

Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…

Over four decades, Dr Tezer Kutluk, Scientific Director of Medicana Health group and Chair of the Department of Pediatric Oncology at Medicana Hospitals, Turkey, has witnessed the transformation of cancer care—from the early days of pediatric oncology to the era…

Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…

How Professor Nagi El Saghir Changed the Language of Cancer in the Middle East and Helped Redefine Global Oncology The airport in Beirut looked very different in 1971. Families walked all the way to the aircraft. Parents accompanied their children…

We often describe progress in oncology through the language of innovation. New drugs. New technologies. New discoveries. Yet scientific breakthroughs rarely change cancer care on their own. They require people willing to pursue difficult ideas, build institutions, challenge accepted thinking,…

Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…

From crowded oncology wards in Cairo to international leadership in cancer education, Dr. Mohamed Emam Sobeih has built a career shaped by one central belief: treating cancer requires more than medicine alone. At the National Cancer Institute Egypt, where Dr…

Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…

As a medical student, we had a lecture on how to deliver bad news.Then, as an oncology fellow, we had it again.And as frontline clinicians, we practice it every day. “Your child has leukemia…You have cancer…Your child has Ewing sarcoma…You…

In oncology, we are trained to deliver hope alongside difficult truths. We speak about survival rates, probabilities, and outcomes. In conflict settings, those terms lose stability. What does survival mean when hospitals are destroyed, treatments cannot reach patients, and people…